News & Updates

Patients with obstructive hypertrophic cardiomyopathy (oHCM) can derive broad clinical benefits from treatment with aficamten, which include complete haemodynamic response and improved exercise capacity among others, as shown by the results of the SEQUOIA-HCM study.

A longer DTBT of up to 180 min is not associated with worse clinical outcomes at 30 days and 1 year in patients with STEMI presenting in Killip classes I–III, according to an analysis of data from the Singapore Myocardial Infarction Registry

Holding or decreasing the dose of outpatient beta blocker therapy does not seem to affect the incidence of tachyarrhythmias in patients with heart failure with reduced ejection fraction (HFrEF) admitted for acute decompensated heart failure (ADHF), reports a study.

People living with HIV (PWH) on statin therapy who have certain metabolic risk factors, such as obesity and prediabetes, are at greater risk of developing diabetes mellitus (DM), reports a study. This association is also present in those treated with placebo.

An analysis using the UK Biobank dataset shows a robust inverse association between well-being and risk of cardiovascular diseases (CVDs), underpinning the protective effect of higher well-being on the four major CVDs evaluated: coronary heart disease, MI, heart failure (HF), and stroke.